SCHEMBL18060894

SCHEMBL18060894

C=C(C)C(=O)Nc1cccc(Sc2c(OC)nc(N3CCOCC3)nc2OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ KCNQ3 O43525 2/20 0.42
▸ KCNQ2 O43526 2/20 0.42
▸ MTOR P42345 4/20 0.41
▸ PIK3CA P42336 4/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ MAPT P10636 3/20 0.40
▸ POLB P06746 3/20 0.40
▸ TP53 P04637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18061042 0.90 MAPT (0.41) SMN1; SMN2RAB9AMAPTPOLBNPC1
SCHEMBL18060751 0.87 EGFR (0.49) —
SCHEMBL18060670 0.86 KCNQ3 (0.47) SMN1; SMN2RAB9AL3MBTL1KCNQ3KCNQ2
SCHEMBL18060776 0.85 KDM4E (0.48) RAB9AHTTKMT2AMEN1HSD17B10
SCHEMBL12806147 0.79 KCNQ3 (0.42) SMN1; SMN2L3MBTL1KCNQ3KCNQ2MTOR
SCHEMBL12806115 0.77 MAPT (0.43) SMN1; SMN2RAB9AL3MBTL1KMT2AMEN1
SCHEMBL18060648 0.77 PLK4 (0.46) L3MBTL1MTORPIK3CAKMT2AMEN1
SCHEMBL12806084 0.77 UCHL3 (0.51) —
SCHEMBL12806382 0.76 TDP1 (0.41) L3MBTL1KMT2AMEN1USP2MAPT
SCHEMBL1276167 0.76 SMN1; SMN2 (0.44) SMN1; SMN2RAB9AKMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205647-B1 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2020-05-13 — — EP disclosed
EP-3205647-A2 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Memorial Sloan-Kettering Cancer Center (US) 2017-08-16 — — EP disclosed
EP-2467142-B1 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders SLOAN KETTERING INST CANCER (US) 2016-09-21 — — EP disclosed
Send feedback